4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride
• 英文别名: Vandetanib hydrochloride；N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine;hydrochloride
• 化学式: C₂₂H₂₄BrFN₄O₂*ClH
• 分子量: 511.822
• InChiKey: KVBQCJXMSFJOFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.43
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  59.5
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 凡德他尼
  参考文献：
  名称：

  QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS

  摘要：

  公开号：

  EP1244647B1
• 作为产物：
  描述：

  6-methoxy-7-(piperidin-4-ylmethoxy)-3-((pivaloyloxy)methyl)-3,4-dihydroquinazolin-4-one 在 盐酸 、 氯化亚砜 、 氨 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 23.0h， 生成 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride
  参考文献：
  名称：

  Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

  摘要：

  We have previously shown that 4-anilinoquinazolines can be potent inhibitors of vascular endothelial growth factor (VEGF) receptor (Flt-1 and KDR) tyrosine kinase activity. A novel subseries of 4-anilinoquinazolines that possess basic side chains at the C-7 position of the quinazoline nucleus have been synthesized. This subseries contains potent, nanomolar inhibitors of KDR (median IC50 0.02 muM, range 0.001-0.04 muM), which are comparatively less potent vs Flt-1 tyrosine kinase (median IC50 0.55 muM, range 0.02-1.6 muM). The compounds also retain some inhibitory activity against the tyrosine kinase associated to the endothelial growth factor receptor (EGFR) (median IC50 0.2 muM, range 0.075-0.8 muM) but demonstrate selectivity vs that associated to the FGF receptor 1 (median IC50 2.5 muM, range 0.9-19 muM). This selectivity profile is also evident in a growth factor-stimulated human endothelial cell (HUVEC) proliferation assay (i.e., inhibition of VEGF > EGF > FGF), with inhibition of VEGF-induced proliferation being achieved at nanomolar concentrations (median IC50 0.06 muM). Further examination of compound 2 (ZD6474) in recombinant enzyme assays revealed excellent selectivity for the inhibition of KDR tyrosine kinase (IC50 0.04 muM) vs the kinase activity of erbB2, MEK, CDK-2, Tie-2, IGFR-1R, PDK, PDGFRbeta, and AKT (IC50 range: 1.1 to >100 muM). Anilinoquinazolines possessing basic C-7 side chains exhibited markedly improved aqueous solubility over previously described anilinoquinazolines possessing neutral C-7 side chains (up to 500-fold improvement at pH 7.4). In addition, aqueous solubility of the neutral fraction present at pH 7.4 of the basic subseries of anilinoquinazoline proved to be higher than that of the neutral analogue 1 (ZD4190). Oral administration of representative compounds to mice (50 mg/kg) produced plasma levels between 0.2 and 3 muM at 24 h after dosing. Our development candidate 2 demonstrated a very attractive in vitro profile combined with excellent solubility (330 muM at pH 7.4) and good oral bioavailability in rat and dog (>80 and >50%, respectively). This compound demonstrated highly significant, dose-dependent, antitumor activity in athymic mice. Once daily oral administration of 100 mg/kg of compound 2 for 21 days inhibited the growth of established Calu-6 lung carcinoma xenografts by 79% (P < 0.001, Mann Whitney rank sum test), and substantial inhibition (36%, P < 0.02) was evident with 12.5 mg/kg/day.

  DOI：

  10.1021/jm011022e

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES EN TANT QU'INHIBITEURS DU FACTEUR DE CROISSANCE ENDOTHELIALE VASCULAIRE (VEGF)
  申请人：ASTRAZENECA AB

  公开号：WO2001032651A1

  公开（公告）日：2001-05-10

  The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C¿1-3?alkyl; X?1¿ represents -O-; R2 is selected from one of the following three groups: 1) C¿1-5?alkylR?3¿ (wherein R3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C¿1-4?alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR?3¿ (wherein R3 is as defined hereinbefore); 3) C¿2-5?alkynylR?3¿ (wherein R3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及式（I）的喹噁啉衍生物，其中m为1至3的整数；R1代表卤素或C1-3烷基；X1代表-O-；R2从以下三组中选择一组：1）C1-5烷基R3（其中R3是哌啶-4-基，可以带有一个或两个取自羟基、卤素、C1-4烷基、C1-4羟基烷基和C1-4烷氧基的取代基）；2）C2-5烯基R3（其中R3如前所定义）；3）C2-5炔基R3（其中R3如前所定义）；其中任何烷基、烯基或炔基可以带有一个或多个取自羟基、卤素和氨基的取代基；以及它们的盐；制备它们的过程，含有式（I）化合物或其药学上可接受的盐作为活性成分的制药组合物。式（I）化合物及其药学上可接受的盐抑制VEGF的作用，这是治疗包括癌症和类风湿性关节炎在内的多种疾病状态的有价值的特性。
• Quinazoline derivatives as VEGF inhibitors
  申请人：Thomas Peter Andrew

  公开号：US20070265286A1

  公开（公告）日：2007-11-15

  The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R 1 represents halogeno or C 1-3 alkyl; X 1 represents —O—; R 2 is selected from one of the following three groups: 1) C 1-5 alkylR 3 (wherein R 3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 alkoxy; 2) C 2-5 alkenylR 3 (wherein R 3 is as defined hereinbefore); 3) C 2-5 alkynylR 3 (wherein R 3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及式（I）的喹唑啉衍生物，其中m是1到3的整数; R1代表卤素或C1-3烷基; X1代表—O—; R2从以下三个组中选择一个：1）C1-5烷基R3（其中R3是哌啶基-4-基，可以带有一个或两个从羟基，卤素，C1-4烷基，C1-4羟基烷基和C1-4烷氧基中选择的取代基; 2）C2-5烯基R3（其中R3如上所定义）; 3）C2-5炔基R3（其中R3如上所定义）; 其中任何烷基，烯基或炔基可以带有一个或多个从羟基，卤素和氨中选择的取代基;以及它们的盐;制备它们的过程，包含式（I）的化合物或其药学上可接受的盐作为活性成分的制药组合物。式（I）的化合物和其药学上可接受的盐抑制VEGF的作用，在治疗包括癌症和类风湿性关节炎在内的多种疾病状态中具有价值的性质。
• Combination therapy
  申请人：Wedge Robert Stephen

  公开号：US20060142316A1

  公开（公告）日：2006-06-29

  The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises one of: the administration of ZD6474 in combination with 5-FU; the administration of ZD6474 in combination with CPT-11; and the administration of ZD6474 in combination with 5-FU and CPT-11; to a pharmaceutical composition comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11; to a combination product comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11, for use in a method of treatment of a human or animal body by therapy; to a kit comprising one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11; to the use of one of: ZD6474 and 5-FU; ZD6474 and CPT-11; and ZD6474 and 5-FU and CPT-11, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

  本发明涉及一种用于在温血动物（例如人类）中产生抗血管生成和/或降低血管通透性的方法，该温血动物可以选择性地接受电离辐射治疗，特别是一种用于治疗癌症的方法，特别是涉及实体肿瘤的癌症，其中包括以下之一：联合使用ZD6474和5-FU的给药；联合使用ZD6474和CPT-11的给药；以及联合使用ZD6474和5-FU和CPT-11的给药；一种药物组合物，其包括以下之一：ZD6474和5-FU；ZD6474和CPT-11；以及ZD6474和5-FU和CPT-11；用于治疗人体或动物体的治疗方法；一种工具包，其包括以下之一：ZD6474和5-FU；ZD6474和CPT-11；以及ZD6474和5-FU和CPT-11；在制造用于在温血动物（例如人类）中产生抗血管生成和/或降低血管通透性的药物时，使用以下之一：ZD6474和5-FU；ZD6474和CPT-11；以及ZD6474和5-FU和CPT-11。
• Combination therapy comprising zd6474 and a taxane
  申请人：Wedge Robert Stephen

  公开号：US20050043395A1

  公开（公告）日：2005-02-24

  The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, particularly a method for the treatment of a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with a taxane; to a pharmaceutical composition comprising ZD6474 and a taxane; to a combination product comprising ZD6474 and a taxane for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and a taxane; to the use of ZD6474 and a taxane in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

  本发明涉及一种在温血动物（如人类）中产生抗血管生成和/或血管通透性降低效果的方法，特别是一种治疗涉及实体肿瘤的癌症的方法，该方法包括与紫杉醇联合使用ZD6474的给药；一种包含ZD6474和紫杉醇的制药组合物；一种包含ZD6474和紫杉醇的联合产品，用于治疗人类或动物体的疗法；一种包含ZD6474和紫杉醇的工具包；使用ZD6474和紫杉醇制造药物，用于在温血动物（如人类），可选地正在接受电离辐射治疗的情况下产生抗血管生成和/或血管通透性降低效果。
• Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
  申请人：Wedge Robert Stephen

  公开号：US20050222183A1

  公开（公告）日：2005-10-06

  The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with ionising radiation; and to the use of ZD6474 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

  本发明涉及一种在温血动物（例如人类）中产生抗血管生成和/或血管通透性降低作用的方法，特别是一种用于治疗癌症的方法，特别是涉及实体肿瘤的癌症的方法，该方法包括与电离辐射联合使用ZD6474的给药；以及使用ZD6474制造药物，用于在正在接受电离辐射治疗的温血动物（例如人类）中产生抗血管生成和/或血管通透性降低作用。